News Square
Global Crypto News · Real-time Aggregation
📚 Deep Analysis
More →GRVT Burns 1.1 Million Tokens as Countdown to Grvt 2.0 Begins
<strong>[PRESS RELEASE – Singapore, Singapore, October 20th, 2026]</strong> <strong>The discretionary buyback represents close to 1% of circulating supply and precedes four planned product milestones culminating in Grvt 2.0.</strong> <a href="https://grvt.io/" rel="nofollow noopener" target="_blank">>Grvt</a>, a self-custodial trading platform built on its own zero-knowledge (ZK) chain, announced that the Foundation’s token issuer has completed its first GRVT token buyback, purchasing and burning 1.1 million GRVT tokens on the open market. The transaction permanently removed close to 1% of GRVT’s circulating supply at the time of purchase. It marks the first of five milestones ahead of the planned launch of Grvt 2.0 at the end of November 2026. <strong>A Discretionary Buyback with On-Chain Verification</strong> The Foundation’s token issuer intends to conduct further buybacks on a monthly basis. Each transaction remains entirely at the issuer’s discretion, with no predetermined purchase amount or guaranteed schedule. Buybacks are executed through an independent execution partner, with purchased tokens transferred to a designated burn address and permanently removed from circulation. The transactions can be independently verified through the <a href="https://grvt.io/exchange/buybacks" rel="nofollow noopener" target="_blank">>public buyback dashboard</a>, which records the number of tokens purchased and burned, the percentage of circulating supply represented, cumulative burns and on-chain transaction hashes. “The GRVT token is an important part of the ecosystem we are building,” said <strong>Hong, co-founder and CEO of Grvt</strong>. “We welcome the issuer’s buybacks as a demonstration of its long-term commitment to the ecosystem and community. Grvt is expanding its products and markets, and the issuer’s buybacks sit alongside that as a supportive mechanism aimed at reducing circulating token supply.” <strong>Grvt Outlines Four Product Milestones</strong> The announcement follows GRVT’s token generation event in July 2026 and precedes a series of planned launches. <strong>Grvt Earn, scheduled for the End of October,</strong> will introduce yield opportunities backed by tokenized assets, with target yields of up to 11%. Potential returns are expected to derive from underlying asset cash flows, including interest, premiums and invoice-related income. Asset-supplying partners will be announced at launch. Target yields are not guaranteed. <strong>Stable Funding Perps, scheduled for November,</strong> will introduce perpetual futures linked to commodities, stocks, foreign exchange and indices. The contracts are planned to carry zero trading fees and use once-daily funding. Grvt aims to list more than 1,000 markets by the end of December 2026. <strong>Yield as Margin, also scheduled for November,</strong> will allow eligible Grvt Earn balances to support trading positions while continuing to accrue yield, subject to applicable product terms
OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work
OpenAI has bought Orchestra Bio, a San Francisco startup whose AI agents help drug companies keep sprawling development programs on schedule, the ChatGPT maker <a href="https://openai.com/index/openai-to-acquire-orchestra-bio/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>announced Tuesday</a>. “Our goal is to help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner,” OpenAI said in the announcement. Orchestra’s team and platform will be folded into <a href="https://openai.com/rosalind/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>Rosalind</a>, OpenAI’s family of AI models and tools for biologists and chemists. The financial terms were not disclosed. Getting a new medicine from first idea to U.S. approval takes time—up to 15 years according to OpenAI. Every month shaved off that timeline is a month earlier that a new treatment can reach the people waiting for it, and a month earlier that the company can generate cash. The process is also absurdly expensive: bringing one approved drug to market can cost more than <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12668846/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>$2.6 billion</a>, and <a href="https://arxiv.org/pdf/2106.05386" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">fewer than 10%</a> of candidates that enter human testing ever make it to pharmacy shelves. Beyond the science itself, OpenAI says drug teams have to coordinate work across internal departments and outside partners, often relying on systems that don’t talk to each other. Those partners usually include contract research organizations, the outside labs hired to run studies, and contract manufacturers that produce the experimental drug. Orchestra’s AI agents—software that can watch over tasks and flag problems on its own—work out which activities and deadlines take the hit, gather the relevant information and compare ways to respond, while scientists and program leaders make the final call. Founded in the fall of 2022, Orchestra raised its <a href="https://jobs.8vc.com/companies/orchestra/jobs/28818089-senior-software-engineer" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>seed round</a> from Andreessen Horowitz, Definition Capital, Insight Partners, and 8VC, and about $20 million in total, according to <a href="https://www.caplight.com/company/orchestra-bio" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">Caplight data</a>. The company should not be confused with Orchestra BioMed, an unrelated Nasdaq-listed medical device maker that trades under the ticker OBIO. In April, OpenAI launched <a href="https://decrypt.co/364783/openai-gpt-rosalind-drug-discovery-life-sciences-model" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">GPT-Rosalind</a>, a model built specifically for biology and dru
Elice shares rebound as CEO expects revenue to double this year.
According to CoinWorld news, after its first day of trading on KOSDAQ, Elice's stock price rose by the daily limit within a single day, following a sharp 32% decline earlier. As a South Korean AI computing provider, Elice recovered most of its first-day losses, buoyed by optimistic earnings reports from U.S. tech companies. Its CEO stated that revenue is expected to at least double this year.
DeFi total value locked daily snapshot reports 89.859 billion USD
CoinWorld data: The daily snapshot for 2026-10-21 shows that total DeFi value locked stands at $89.859 billion, an increase of 1.15% compared with the previous statistical period using the same methodology.
The overall return rate of stock strategy private funds in the first three quarters was 1.92%, and the proportion of products with positive returns was 51.69%.
According to Bijie Network news, [The overall return rate of stock strategy private equity products in the first three quarters was 1.92%, and the proportion of products with positive returns was 51.69%] Cailian Press, October 21 - Data from Simuwang shows that among 6,786 stock strategy private equity products with performance records, the overall return rate in the first three quarters was 1.92%, of which 3,508 products achieved positive returns, accounting for 51.69%.
Nvidia plans to invest in Pigment, raising $250 million.
Pigment announced the completion of a $250 million funding round at a valuation of $2.3 billion, according to BiJie Network. The round was led by Scaleup Europe Fund, with Nvidia planning to participate, alongside existing investors and the World Innovation Lab.
Sydney, Oct 21 (Cailian Press) — Strategists at Commonwealth Bank of Australia said that if Middle East tensions ease and energy prices retreat, safe-haven demand for the dollar will cool, but continued foreign capital inflows into the United States will support a mild upward trend for the dollar over the coming months.
CoinWorld news, Cailian Press, October 21: Commonwealth Bank of Australia strategists said that if Middle East tensions ease and energy prices fall, safe-haven buying of the dollar will cool, but continued foreign capital inflows into the United States will support a mild upward move in the dollar over the coming months.
Governor of Leningrad Oblast, Russia: Three drones were shot down.
Leningrad Oblast Governor: Three drones were shot down.
Germany's national bank opens up crypto retail, Tether makes a heavy bet on AI computing power infrastructure.
According to bbx, citing CoinWorld news, Germany's Sparkassen (savings banks) have officially opened mobile crypto trading, partnering with Dekabank to build a compliant channel that brings millions of retail depositors into the Web3 era with an extremely low barrier to entry. Meanwhile, stablecoin leader Tether participated in Tenstorrent's Series E funding round of up to $1.5 billion, using profits from decentralized payments to make a major push into the underlying hardware of AI chips. The market is showing a dual evolution: traditional national-level financial institutions are opening decentralized asset allocation to long-tail retail customers through mature compliant custody infrastructure, while crypto-native giants are leveraging abundant liquidity premiums to pursue deep strategic M&A in artificial intelligence and computing hardware.
Meta, Tesla, and IBM will release their third-quarter earnings reports, with the market focused on AI profitability.
According to CoinWorld news, Meta, Tesla, and IBM will hold their third-quarter earnings conference calls at 04:30, 05:00, and 05:30 (UTC+8) tomorrow morning, respectively, with the market focused on the profitability of the three companies' AI investments. Meta needs to prove that advertising growth can cover computing power expenses, IBM needs to convert AI orders into revenue, and Tesla needs to balance automotive business profits with long-term investment. Wall Street options markets are pricing in roughly 7% two-way volatility for the three companies. On-chain data shows that Meta has seen $10 million-level long position increases, IBM trading is quiet, and Tesla has reduced its holdings as prices rise.